Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CDKN2A mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	palbociclib Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) palbociclib Sensitive : C3 ASCO 2023 - 3d	palbociclib Sensitive: C3 – Early Trials ASCO 2023 - 3 days palbociclib Sensitive : C3 ASCO 2023 - 3 days - (New C3)
CDKN2A mutation	Triple Negative Breast Cancer	CDKN2A mutation	Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
CDKN2A mutation	Breast Cancer	CDKN2A mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
CDKN2A mutation	Gallbladder Cancer	CDKN2A mutation	Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A mutation	Clear Cell Renal Cell Carcinoma	CDKN2A mutation	Clear Cell Renal Cell Carcinoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDKN2A mutation	Pancreatic Cancer	CDKN2A mutation	Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A mutation	Solid Tumor	CDKN2A mutation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A mutation	Melanoma	CDKN2A mutation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A mutation	Urothelial Cancer	CDKN2A mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A mutation	Biliary Tract Cancer	CDKN2A mutation	Biliary Tract Cancer	toripalimab Resistant: C3 – Early Trials toripalimab Resistant : C3	toripalimab Resistant: C3 – Early Trials toripalimab Resistant : C3
CDKN2A mutation	Non Small Cell Lung Cancer	CDKN2A mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CDKN2A mutation	Penile Cancer	CDKN2A mutation	Penile Cancer	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
CDKN2A mutation	Non Small Cell Lung Cancer	CDKN2A mutation	Non Small Cell Lung Cancer	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
CDKN2A mutation	Melanoma	CDKN2A mutation	Melanoma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D